Hyperprogressive disease in leiomyosarcoma: a threat to the use of single-agent anti-PD-(L)1 therapy?

References

• 1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J. Clin. 70(1), 7–30 (2020).
  MedlineGoogle Scholar
• 2. Guo X, Jo VY, Mills AM et al. Clinically relevant molecular subtypes in leiomyosarcoma. Clin. Cancer Res. 21(15), 3501–3511 (2015).
  Medline CASGoogle Scholar
• 3. Beck AH, Lee C-H, Witten DM et al. Discovery of molecular subtypes in leiomyosarcoma through integrative molecular profiling. Oncogene 29(6), 845–854 (2010).
  Medline CASGoogle Scholar
• 4. Judson I, Verweij J, Gelderblom H et al. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncol. 15(4), 415–423 (2014).
  Medline CASGoogle Scholar
• 5. Ryan CW, Merimsky O, Agulnik M et al. PICASSO III: a phase III, placebo-controlled study of doxorubicin with or without palifosfamide in patients with metastatic soft tissue sarcoma. J. Clin. Oncol. 34(32), 3898–3905 (2016).
  Medline CASGoogle Scholar
• 6. Tap WD, Papai Z, Van Tine BA et al. Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 18(8), 1089–1103 (2017).
  Medline CASGoogle Scholar
• 7. D'Ambrosio L, Touati N, Blay J-Y et al. Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: a propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Cancer 126(11), 2637–2647 (2020).
  MedlineGoogle Scholar
• 8. Pautier P, Italiano A, Piperno-Neumann S et al. LBA59 LMS-04 study: A randomised, multicenter, phase III study comparing doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin in non-progressive patients as first-line therapy, in patients with metastatic or unresectable leiomyosarcoma – a French Sarcoma Group study. Ann. Oncol. 32, S1335–S1336 (2021).
  Google Scholar
• 9. Borghaei H, Paz-Ares L, Horn L et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J. Med. 373(17), 1627–1639 (2015).
  Medline CASGoogle Scholar
• 10. Atkins MB, Plimack ER, Puzanov I et al. Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial. Lancet Oncol. 19(3), 405–415 (2018).
  Medline CASGoogle Scholar
• 11. Larkin J, Chiarion-Sileni V, Gonzalez R et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373(1), 23–34 (2015).
  Medline CASGoogle Scholar
• 12. Tawbi HA, Burgess M, Bolejack V et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol. 18(11), 1493–1501 (2017).
  Medline CASGoogle Scholar
• 13. D'Angelo SP, Mahoney MR, Van Tine BA et al. Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. Lancet Oncol. 19(3), 416–426 (2018).
  MedlineGoogle Scholar
• 14. Ben-Ami E, Barysauskas CM, Solomon S et al. Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: results of a phase 2 study. Cancer 123(17), 3285–3290 (2017).
  Medline CASGoogle Scholar
• 15. Pollack SM, Ingham M, Spraker MB, Schwartz GK. Emerging targeted and immune-based therapies in sarcoma. J. Clin. Oncol. 36(2), 125–135 (2017).
  MedlineGoogle Scholar
• 16. De Wispelaere W, Annibali D, Tuyaerts S, Lambrechts D, Amant F. Resistance to immune checkpoint blockade in uterine leiomyosarcoma: what can we learn from other cancer types? Cancers 13(9), 2040 (2021).
  MedlineGoogle Scholar
• 17. Galluzzi L, Buque A, Kepp O, Zitvogel L, Kroemer G. Immunological effects of conventional chemotherapy and targeted anticancer agents. Cancer Cell 28(6), 690–714 (2015).
  Medline CASGoogle Scholar
• 18. Pollack SM, Redman MW, Baker KK et al. Assessment of doxorubicin and pembrolizumab in patients with advanced anthracycline-naive sarcoma: a phase 1/2 nonrandomized clinical trial. JAMA Oncol. 6(11), 1778–1782 (2020).
  MedlineGoogle Scholar
• 19. Livingston MB, Jagosky MH, Robinson MM et al. Phase II study of pembrolizumab in combination with doxorubicin in metastatic and unresectable soft tissue sarcoma. Clin. Cancer Res. 27(23), 6424–6431 (2021).
  Medline CASGoogle Scholar
• 20. Wilky BA, Trucco MM, Subhawong TK et al. Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, Phase 2 trial. Lancet Oncol. 20(6), 837–848 (2019).
  Medline CASGoogle Scholar
• 21. Smrke A, Ostler A, Napolitano A et al. 1526MO GEMMK: A phase I study of gemcitabine (gem) and pembrolizumab (pem) in patients (pts) with leiomyosarcoma (LMS) and undifferentiated pleomorphic sarcoma UPS. Ann. Oncol. 32, S1114 (2021).
  Google Scholar
• 22. Klemen ND, Hwang S, Bradic M et al. 1527MO Biomarkers of response and hyperprogression in patients with sarcoma treated with checkpoint blockade. Ann. Oncol. 32, S1114–S1115 (2021).
  Google Scholar
• 23. Birdi HK, Jirovec A, Cortés-Kaplan S et al. Immunotherapy for sarcomas: new frontiers and unveiled opportunities. J. Immunother. Cancer 9(2), e001580 (2021).
  MedlineGoogle Scholar
• 24. Martín-Broto J, Moura DS, Van Tine BA. Facts and hopes in immunotherapy of soft-tissue sarcomas. Clin. Cancer Res. 26(22), 5801–5808 (2020).
  Medline CASGoogle Scholar
• 25. Seymour L, Bogaerts J, Perrone A et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 18(3), e143–e152 (2017).
  MedlineGoogle Scholar
• 26. Adashek JJ, Subbiah IM, Matos I et al. Hyperprogression and immunotherapy: fact, fiction, or alternative fact? Trends Cancer 6(3), 181–191 (2020).
  Medline CASGoogle Scholar
• 27. Ferrara R, Mezquita L, Texier M et al. Hyperprogressive disease in patients with advanced non-small-cell lung cancer treated with PD-1/PD-L1 inhibitors or with single-agent chemotherapy. JAMA Oncol. 4(11), 1543–1552 (2018).
  MedlineGoogle Scholar
• 28. Fuentes-Antrás J, Provencio M, Díaz-Rubio E. Hyperprogression as a distinct outcome after immunotherapy. Cancer Treat. Rev. 70, 16–21 (2018).
  Medline CASGoogle Scholar
• 29. Champiat S, Ferrara R, Massard C et al. Hyperprogressive disease: recognizing a novel pattern to improve patient management. Nat. Rev. Clin. Oncol. 15(12), 748–762 (2018).
  Medline CASGoogle Scholar
• 30. Kato S, Goodman AM, Walavalkar V, Barkauskas DA, Sharabi A, Kurzrock R. Hyper-progressors after immunotherapy: analysis of genomic alterations associated with accelerated growth rate. Clin. Cancer Res. 23(15), 4242–4250 (2017).
  Medline CASGoogle Scholar
• 31. Singavi AK, Menon S, Kilari D et al. Predictive biomarkers for hyper-progression (HP) in response to immune checkpoint inhibitors (ICI) – analysis of somatic alterations (SAs). Ann. Oncol. 28, v405 (2017).
  Google Scholar
• 32. Manzoni M, Bolognesi MM, Antoranz A et al. The adaptive and innate immune cell landscape of uterine leiomyosarcomas. Sci. Rep. 10(1), 1–10 (2020).
  MedlineGoogle Scholar
• 33. Peng W, Chen JQ, Liu C et al. Loss of PTEN promotes resistance to T cell-mediated immunotherapy. Cancer Discov. 6(2), 202–216 (2016).
  Medline CASGoogle Scholar
• 34. George S, Miao D, Demetri GD et al. Loss of PTEN is associated with resistance to anti-PD-1 checkpoint blockade therapy in metastatic uterine leiomyosarcoma. Immunity 46(2), 197–204 (2017).
  Medline CASGoogle Scholar